Clinical Trial

Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients

Study acronym: UNZUELUZON ALS
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited. Previous genetic, proteomic, imaging, and electrophysiological studies have identified potential biomarkers and phenotype modifiers, improving the understanding of motor neuron degeneration mechanisms. However, these findings have not yet been translated into a clinically useful biomarker algorithm. This observational study aims to develop a biomarker panel to support the diagnosis, prognosis, and stratification of patients with ALS. Clinical and molecular biomarkers previously associated with ALS phenotypes will be analyzed simultaneously and integrated into a multivariable predictive model. Clinical data and biological samples will be collected and analyzed to identify combinations of biomarkers associated with ALS phenotypes.
Trial Details
NCT Number NCT07737977
Lead Sponsor University Hospital, Montpellier
Collaborators: Hospital Universitari Vall d'Hebron Research Institute
Conditions ALS (Amyotrophic Lateral Sclerosis)
Enrollment 200 participants
Start Date 2026-08
Primary Completion 2029-02 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-30